These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 23033854)

  • 1. Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients.
    Bertout S; Drakulovski P; Kouanfack C; Krasteva D; Ngouana T; Dunyach-Rémy C; Dongtsa J; Aghokeng A; Delaporte E; Koulla-Shiro S; Reynes J; Mallié M
    Clin Microbiol Infect; 2013 Aug; 19(8):763-9. PubMed ID: 23033854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptococcus neoformans isolates from Yaoundé human immunodeficiency virus-infected patients exhibited intra-individual genetic diversity and variation in antifungal susceptibility profiles between isolates from the same patient.
    Kammalac Ngouana T; Drakulovski P; Krasteva D; Kouanfack C; Reynes J; Delaporte E; Boyom FF; Mallié M; Bertout S
    J Med Microbiol; 2016 Jul; 65(7):579-589. PubMed ID: 27100672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular epidemiology reveals genetic diversity among 363 isolates of the Cryptococcus neoformans and Cryptococcus gattii species complex in 61 Ivorian HIV-positive patients.
    Kassi FK; Drakulovski P; Bellet V; Krasteva D; Gatchitch F; Doumbia A; Kouakou GA; Delaporte E; Reynes J; Mallié M; Menan HIE; Bertout S
    Mycoses; 2016 Dec; 59(12):811-817. PubMed ID: 27461533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates.
    Arsic Arsenijevic V; Pekmezovic MG; Meis JF; Hagen F
    Mycoses; 2014 Jun; 57(6):380-7. PubMed ID: 24438323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.
    Liaw SJ; Wu HC; Hsueh PR
    Clin Microbiol Infect; 2010 Jun; 16(6):696-703. PubMed ID: 19694765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis.
    Illnait-Zaragozí MT; Martínez-Machín GF; Fernández-Andreu CM; Hagen F; Boekhout T; Klaassen CH; Meis JF
    BMC Infect Dis; 2010 Oct; 10():289. PubMed ID: 20920321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya.
    Bii CC; Makimura K; Abe S; Taguchi H; Mugasia OM; Revathi G; Wamae NC; Kamiya S
    Mycoses; 2007 Jan; 50(1):25-30. PubMed ID: 17302744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryptoccocal meningitis in Yaoundé (Cameroon) HIV infected patients: Diagnosis, frequency and Cryptococcus neoformans isolates susceptibility study to fluconazole.
    Kammalac Ngouana T; Dongtsa J; Kouanfack C; Tonfack C; Fomena S; Mallié M; Delaporte E; Boyom FF; Bertout S
    J Mycol Med; 2015 Mar; 25(1):11-6. PubMed ID: 25467817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil.
    Souza LK; Souza Junior AH; Costa CR; Faganello J; Vainstein MH; Chagas AL; Souza AC; Silva MR
    Mycoses; 2010 Jan; 53(1):62-7. PubMed ID: 19500261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
    Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antifungal susceptibilities and molecular typing of sequentially isolated clinical Cryptococcus neoformans strains from Croatia.
    Mlinarić-Missoni E; Hagen F; Chew WHM; Važić-Babić V; Boekhout T; Begovac J
    J Med Microbiol; 2011 Oct; 60(Pt 10):1487-1495. PubMed ID: 21617022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil.
    Almeida AM; Matsumoto MT; Baeza LC; de Oliveira E Silva RB; Kleiner AA; Melhem Mde S; Mendes Giannini MJ;
    FEMS Yeast Res; 2007 Jan; 7(1):152-64. PubMed ID: 17311593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal susceptibility and multilocus sequence typing (MLST) of Cryptococcus neoformans complex from HIV-associated cryptococcal meningitis patients in Manaus, Amazonas, Brazil.
    Alves MJ; Cruz KS; Alves GSB; Grisolia ME; Menescal VVF; do Nascimento IS; Menescal LSF; Pinheiro SB; da Silva FA; Trilles L; de Souza JVB; Lazera MDS; Jackisch-Matsuura AB
    Braz J Microbiol; 2024 Sep; 55(3):2603-2611. PubMed ID: 38755408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study.
    Kassi FK; Drakulovski P; Bellet V; Roger F; Chabrol A; Krasteva D; Doumbia A; Landman R; Kakou A; Reynes J; Delaporte E; Menan HEI; Bertout S
    PLoS Negl Trop Dis; 2019 Nov; 13(11):e0007812. PubMed ID: 31738768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization and antifungal susceptibility of Cryptococcus neoformans strains collected from a single institution in Lima, Peru.
    Bejar V; Tello M; García R; Guevara JM; Gonzales S; Vergaray G; Valencia E; Abanto E; Ortega-Loayza AG; Hagen F; Gutierrez EL
    Rev Iberoam Micol; 2015; 32(2):88-92. PubMed ID: 25556051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil.
    Favalessa OC; de Paula DA; Dutra V; Nakazato L; Tadano T; Lazera Mdos S; Wanke B; Trilles L; Walderez Szeszs M; Silva D; Hahn RC
    J Infect Dev Ctries; 2014 Aug; 8(8):1037-43. PubMed ID: 25116671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China.
    Fan X; Xiao M; Chen S; Kong F; Dou HT; Wang H; Xiao YL; Kang M; Sun ZY; Hu ZD; Wan Z; Chen SL; Liao K; Chu YZ; Hu TS; Zou GL; Hou X; Zhang L; Zhao YP; Xu YC; Liu ZY
    Clin Microbiol Infect; 2016 Oct; 22(10):887.e1-887.e9. PubMed ID: 27432767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antifungal susceptibility profiles of Cryptococcus species isolated from HIV-associated cryptococcal meningitis patients in Zimbabwe.
    Nyazika TK; Herkert PF; Hagen F; Mateveke K; Robertson VJ; Meis JF
    Diagn Microbiol Infect Dis; 2016 Nov; 86(3):289-292. PubMed ID: 27608538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E; Vitali LH; Kress MRVZ; Martinez R
    Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.